Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC FLU Quadrivalent immunogenicity and safety in adults
NCT03718468Phase 3Completed
- Sponsor
- Medigen Biotechnology
- Start
- Oct 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GC Flu Quadrivalent in influenza (2 arms), sponsored by Medigen Biotechnology. Primary endpoints: Geometric Mean Titer Ratio and Seroconversion Rate. Started Oct 2018; status: completed.
02
Drugs
GC Flu Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03718468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718468.